Company Performance Metrics
- Sean Bohen: President and Chief Executive OfficerPast Role: AstraZeneca, Executive Vice-President, Global Medicines Development and Chief Medical Officer
- Sean Bohen: Interim Principal Financial OfficerPast Role: AstraZeneca, Executive Vice-President, Global Medicines Development and Chief Medical Officer
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.
The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design
compounds that are superior to both the current drugs and those in development.
Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.